Literature DB >> 23511341

Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure.

Ryo Sato1, Masashi Mizuno, Toshiyuki Miura, Yoko Kato, Shuichi Watanabe, Daisuke Fuwa, Yoshiaki Ogiyama, Tatsuya Tomonari, Keisuke Ota, Tadashi Ichikawa, Yuichi Shirasawa, Akinori Ito, Atsuhiro Yoshida, Michio Fukuda, Genjiro Kimura.   

Abstract

OBJECTIVE: The sympathetic nervous system plays an important role in blood pressure regulation even in the early stages of chronic kidney disease (CKD).
METHODS: To understand the role of the sympathetic system, we examined the relationship between day/night ratios of both heart rate (HR) and mean arterial pressure (MAP) as well as HR variability (HRV, SD) before and during an 8-week treatment with the angiotensin II receptor blocker (ARB), olmesartan, in 45 patients with CKD.
RESULTS: The day/night HR ratio strongly correlated with the day/night MAP ratio before and during ARB treatment. The ratio of [day/night HR ratio] over [day/night MAP ratio] was increased as renal function deteriorated at baseline (r = -0.31, P = 0.04), and it was attenuated (1.10 ± 0.10 to 1.06 ± 0.10; P = 0.04) and became independent of renal function during ARB treatment (r = -0.04, P = 0.8). ARB increased both the day/night HR ratio (1.17 ± 0.09 to 1.21 ± 0.13; P = 0.04) and HRV (10.6 ± 2.9 to 11.7 ± 4.2; P = 0.04), which were lower when baseline renal function deteriorated.
CONCLUSION: The present study indicates that there exists a close correlation in circadian rhythms between HR and MAP in CKD. Synchronization between the two rhythms was progressively lost as renal function deteriorated, and ARB partly restored the synchronization. These findings suggest that the sympathetic nervous system is activated as renal function deteriorates, and ARB may suppress its activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23511341     DOI: 10.1097/HJH.0b013e32836043c9

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  8 in total

1.  Effect of penehyclidine hydrochloride on heart rate variability in hysteroscopy.

Authors:  Xiao-Bo Liu; Shu Pan; Xi-Ge Yang; Zhi-Wen Li; Qing-Shan Sun; Zhuang Zhao; Hai-Chun Ma; Cheng-Ri Cui
Journal:  Exp Ther Med       Date:  2015-05-18       Impact factor: 2.447

2.  ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.

Authors:  Timothy Kwok; Jason Leung; Elizabeth Barrett-Connor
Journal:  Age Ageing       Date:  2017-01-10       Impact factor: 10.668

Review 3.  Complexities in cardiovascular rhythmicity: perspectives on circadian normality, ageing and disease.

Authors:  Oliver Monfredi; Edward G Lakatta
Journal:  Cardiovasc Res       Date:  2019-09-01       Impact factor: 10.787

Review 4.  Autonomic nervous system dysregulation in pediatric hypertension.

Authors:  Janusz Feber; Marcel Ruzicka; Pavel Geier; Mieczyslaw Litwin
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 5.  Cardiovascular Autonomic Dysfunction in Chronic Kidney Disease: a Comprehensive Review.

Authors:  Ibrahim M Salman
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 6.  Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.

Authors:  Gino Seravalle; Fosca Quarti-Trevano; Jennifer Vanoli; Chiara Lovati; Guido Grassi
Journal:  Clin Auton Res       Date:  2021-02-19       Impact factor: 4.435

Review 7.  The end effector of circadian heart rate variation: the sinoatrial node pacemaker cell.

Authors:  Yael Yaniv; Edward G Lakatta
Journal:  BMB Rep       Date:  2015-12       Impact factor: 4.778

8.  Heart Rate Variability-Guided Training for Improving Mortality Predictors in Patients with Coronary Artery Disease.

Authors:  Agustín Manresa-Rocamora; José Manuel Sarabia; Silvia Guillen-Garcia; Patricio Pérez-Berbel; Beatriz Miralles-Vicedo; Enrique Roche; Néstor Vicente-Salar; Manuel Moya-Ramón
Journal:  Int J Environ Res Public Health       Date:  2022-08-23       Impact factor: 4.614

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.